Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

This study has been completed.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: October 27, 1999
Last updated: January 2, 2014
Last verified: August 2006

The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.

Condition Intervention Phase
Respiratory Distress Syndrome, Adult
Lung Diseases
Procedure: Low Tidal Volume Ventilation
Procedure: Positive End-Expiratory Pressure
Drug: Lysofylline
Drug: Methylprednisolone
Drug: Ketoconazole
Procedure: Fluid Management
Procedure: Pulmonary Artery Catheter
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Factorial Assignment
Primary Purpose: Treatment
Official Title: Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Primary Outcome Measures:
  • Vary by protocol

Study Start Date: September 1994
Study Completion Date: July 2004
  Show Detailed Description


Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women
  • 13 years of age or older
  • ARDS or risk factors for ARDS (patients will be considered at risk if they are critically ill and have trauma, sepsis, shock, pneumonia, inhalation injury, drug overdose, pancreatitis, or hypertransfusion)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000579

  Hide Study Locations
United States, California
University of California
San Francisco, California, United States, 94143
United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80262
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Louisiana
Louisiana State University
New Orleans, Louisiana, United States, 70112
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Baystate Medical Center
Springfield, Massachusetts, United States, 01199
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Mayo Foundation
Rochester, Minnesota, United States, 55905
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27708
Wake Forest University
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15261
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
University of Texas
San Antonio, Texas, United States, 78229-3900
United States, Utah
Latter Day Saints Hospital
Salt Lake City, Utah, United States, 84143
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
United States, Washington
University of Washington
Seattle, Washington, United States, 98105
Canada, British Columbia
University of British Columbia
Vancouver, British Columbia, Canada, V5Z 1M9
Sponsors and Collaborators
Principal Investigator: Edward Abraham, MD University of Colorado, Denver
Principal Investigator: Antonio Anzueto, MD University of Texas
Principal Investigator: Roy Brower, MD Johns Hopkins University
Principal Investigator: Alfred F. Connors, MD University of Virginia
Principal Investigator: Bennett P. deBoisblanc, MD Louisiana State University Health Sciences Center in New Orleans
Principal Investigator: Bennett P. deBoisblanc, MD Louisiana State University Health Science Center
Principal Investigator: Michael Donahoe, MD University of Pittsburgh
Principal Investigator: Kalpalatha K. Guntupalli, MD Baylor College of Medicine
Principal Investigator: Robert D. Hite, MD Wake Forest School of Medicine
Principal Investigator: Rolf Hubmayr, MD Mayo Clinic
Principal Investigator: Neil MacIntyre, MD Duke University
Principal Investigator: Michael A. Matthay, MD University of California, San Francisco
Principal Investigator: Alan Morris, MD Latter Day Saints Hospital
Principal Investigator: Michael J. Murray Mayo Foundation
Principal Investigator: James A. Russell, MD University of British Columbia
Principal Investigator: Gregory A. Schmidt, MD, FCCP University of Chicago
Principal Investigator: David A. Schoenfeld, PhD Massachusetts General Hospital
Principal Investigator: Jay S. Steingrub, MD, FCCP Baystate Medical Center
Principal Investigator: Arthur Wheeler, MD Vanderbilt University
Principal Investigator: Herbert Wiedemann, MD Cleveland Clinic Lerner College of Medicine
  More Information

Additional Information:

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00000579     History of Changes
Other Study ID Numbers: 217, N01 HR16146, N01 HR16147, N01 HR16148, N01 HR16149, N01 HR16150, N01 HR16151, N01 HR16152, N01 HR16153, N01 HR16154, N01 HR16155, N01 HR46054, N01 HR46055, N01 HR46056, N01 HR46057, N01 HR46058, N01 HR46059, N01 HR46060, N01 HR46061, N01 HR46062, N01 HR46063, N01 HR46064, N01 HR56165, N01 HR56166, N01 HR56167, N01 HR56168, N01 HR56169, N01 HR56170, N01 HR56171, N01 HR56172, N01 HR56173, N01 HR56174, N01 HR56175, N01 HR56176, N01 HR56179
Study First Received: October 27, 1999
Last Updated: January 2, 2014
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Acute Lung Injury
Lung Diseases
Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Newborn
Infant, Newborn, Diseases
Infant, Premature, Diseases
Lung Injury
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Methylprednisolone Hemisuccinate
Methylprednisolone acetate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
14-alpha Demethylase Inhibitors
Anti-Infective Agents
Anti-Inflammatory Agents
Antifungal Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors processed this record on February 25, 2015